New clinical data published in European Journal of Radiology demonstrate that the Hygea Co-Ablation System is a safe and feasible option for the treatment of malignant lung tumors. In more than 200 treatment sessions, co-ablation achieved:
• Acceptable adverse event rates, with pneumothorax comparable to conventional cryoablation
• Significantly lower rates of pleural effusion and hemoptysis
• Favorable local tumor control, particularly in tumors ≤3 cm
• Prolonged progression-free survival in small lesions
By integrating the advantages of cryoablation and high-intensity thermal ablation, the Hygea Co-Ablation System enables precise tumor destruction while maintaining a strong safety profile, supporting its role as a promising minimally invasive solution for lung cancer patients.
Source: Zhang et al., European Journal of Radiology, 2026
EN 
